Cytotoxic T lymphocyte antigen-4 regulates development of xenogenic graft versus host disease in mice via modulation of host immune responses induced by changes in human T cell engraftment and gene expression

Clin Exp Immunol. 2021 Dec;206(3):422-438. doi: 10.1111/cei.13659. Epub 2021 Sep 22.

Abstract

Graft versus host disease (GvHD) is a major clinical problem with a significant unmet medical need. We examined the role of cytotoxic T lymphocyte antigen-4 (CTLA-4) in a xenogenic GvHD (xeno-GvHD) model induced by injection of human peripheral mononuclear cells (hPBMC) into irradiated non-obese diabetic (NOD) SCID gamma (NSG) mice. Targeting the CTLA-4 pathway by treatment with CTLA-4 immunoglobulin (Ig) prevented xeno-GvHD, while anti-CTLA-4 antibody treatment exacerbated the lethality and morbidity associated with GvHD. Xeno-GvHD is associated with infiltration of hPBMCs into the lungs, spleen, stomach, liver and colon and an increase in human proinflammatory cytokines, including interferon (IFN)-γ, tumor necrosis factor (TNF)-α and interleukin (IL)-5. Infiltration of donor cells and increases in cytokines were attenuated by treatment with CTLA-4 Ig, but remained either unaffected or enhanced by anti-CTLA-4 antibody. Further, splenic human T cell phenotyping showed that CTLA-4 Ig treatment prevented the engraftment of human CD45+ cells, while anti-CTLA-4 antibody enhanced donor T cell expansion, particularly CD4+ (CD45RO+ ) subsets, including T box transcription factor TBX21 (Tbet)+ CXCR3+ and CD25+ forkhead box protein 3 (FoxP3) cells. Comprehensive analysis of transcriptional profiling of human cells isolated from mouse spleen identified a set of 417 differentially expressed genes (DEGs) by CTLA-4 Ig treatment and 13 DEGs by anti-CTLA-4 antibody treatment. The CTLA-4 Ig regulated DEGs mapped to down-regulated apoptosis, inflammasome, T helper type 17 (Th17) and regulatory T cell (Treg ) pathways and enhanced Toll-like receptor (TLR) receptor signaling, TNF family signaling, complement system and epigenetic and transcriptional regulation, whereas anti-CTLA-4 antibody produced minimal to no impact on these gene pathways. Our results show an important role of co-inhibitory CTLA-4 signaling in xeno-GvHD and suggest the therapeutic utility of other immune checkpoint co-inhibitory pathways in the treatment of immune-mediated diseases driven by hyperactive T cells.

Keywords: CTLA-4; cytokine; gene profile; histopathology; xeno-GvHD.

MeSH terms

  • Alanine Transaminase / blood
  • Animals
  • Antibodies, Monoclonal, Humanized / pharmacology
  • Aspartate Aminotransferases / blood
  • CTLA-4 Antigen / immunology*
  • Cytokines / blood*
  • Graft vs Host Disease / immunology*
  • Heterografts / immunology*
  • Humans
  • Immunoglobulin G / administration & dosage
  • Immunoglobulin G / immunology
  • Ipilimumab / pharmacology
  • Leukocytes, Mononuclear / immunology*
  • Lymphocyte Activation / immunology
  • Mice
  • Mice, Inbred NOD
  • Mice, SCID
  • T-Lymphocytes, Cytotoxic / immunology

Substances

  • Antibodies, Monoclonal, Humanized
  • CTLA-4 Antigen
  • Cytokines
  • Immunoglobulin G
  • Ipilimumab
  • Aspartate Aminotransferases
  • Alanine Transaminase
  • tremelimumab